Notizie AIOM – anno XVII
Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC
March 18, 2019 - The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer (CRC) to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment ...Leggi tutto
FDA Approves Atezolizumab Regimen for Frontline Small Cell Lung Cancer
March 19, 2019 - The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The approval is based on findings from the phase III IMpower133 ...Leggi tutto
FDA Halts Enrollment on Venetoclax Myeloma Trials
March 19, 2019 - The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche). AbbVie ...Leggi tutto
Management Board re-elects Christa Wirthumer-Hoche as chair
March 21, 2019 - EMA’s Management Board today re-elected Christa Wirthumer-Hoche as its chair for a three-year mandate. Dr Wirthumer-Hoche is Head of the Austrian Medicines and Medical Devices Agency, a post she has held since October 2013. This is her second and final ...Leggi tutto
FDA Extends Review Period for Selinexor in Myeloma
March 15, 2019 - The FDA has added 3 months to the review period for a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma, making the new action date July 6, 2019. Karyopharm Therapeutics, Inc, the manufacturer of ...Leggi tutto